St. Jude Medical Inc. (STJ): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

By Zacks Investment Research,

Shutterstock photo

St. Jude's preliminary fourth-quarter 2014 results reflect strong momentum at the company's CardioMEMS technology and Atrial Fibrillation business. Most of the segments are expected to report within or above the company's previously issued guidance, which is a positive in our view. We note that the company's top line incorporates a considerable negative impact from recent foreign currency movements. In fact, U.S. manufacturers such as St. Jude that generate a significant portion of their revenues from overseas are being hurt by a strengthening U.S. dollar, which has benefited from more upbeat U.S. economic prospects compared to the rest of the world. We feel that the strong U.S. dollar which is impacting the company's revenues will also hurt its bottom line. Nevertheless, an expanding and innovative product portfolio, accretive acquisitions and aggressive share buyback programs will drive growth in 2015 and beyond. Considering these factors, we maintain Neutral recommendation and set a target price of $70.00.


Headquartered in St. Paul, MN, St. Jude Medical Inc. (STJ) is a leading global manufacturer and distributor of innovative cardiovascular and implantable neurostimulation medical devices.

St. Jude reported net sales of $5.5 billion in 2013. In the nine months ended Sep 27, 2014, sales increased 2.5% year over year to $4.18 billion. U.S. revenues grew 1.2% to $2 billion while international revenues scaled 3.8% to $2.2 billion.

On Jan 28, 2014, St. Jude announced consolidation of two of its operating divisions Implantable Electronic Systems Division (IESD) and Cardiovascular & Ablation Technologies Division (CATD) -- into a single operating unit, which derives revenues from six principal product categories. The integration has been conducted in a phased approach in 2014.

The company's six principal product categories are as follows:

Tachycardia Implantable Cardioverter Defibrillator (ICD) systems (31.6% of total revenues in the first nine months of 2014)

Bradycardia pacemaker (pacemaker) systems (18.8%)

Atrial Fibrillation (AF) products (18.2%)

Vascular products (12.5%)

Structural Heart products (11.5%)

Neuromodulation products (7.4%)

St. Jude Medical Inc. (STJ): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ST JUDE MEDICAL (STJ): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing Stocks
Referenced Stocks: STJ , ICD , AF

More from


Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by